Why Waters Corp Shares Are Surging Today

Loading...
Loading...
  • Waters Corp WAT reported first-quarter FY22 revenue growth of 16% year-on-year in CC to $690.6 million, above the consensus of $632.8 million.
  • Sales into the pharmaceutical market increased 19% in CC, sales into the industrial market increased 17% in CC, and sales into the academic and government markets increased 4% in CC.
  • Recurring revenues increased 9% in CC, while instrument system sales increased 26% in CC.
  • Geographically, sales in Asia increased 14%, sales in the Americas increased 26% (with U.S. sales growing 28%), and sales in Europe increased 9% in CC.
  • The non-GAAP operating income margin expanded by 170 basis points to 30.3%.
  • Non-GAAP EPS of $2.80 beat the consensus of $2.32.
  • Waters generated $197.96 million in operating cash flow.
  • "This was a record first quarter for Waters' sales, led by instruments which grew 26% in constant currency, while our recurring revenues grew 9% in constant currency, reflecting continued demand across our geographies and end-markets," CEO Dr. Udit Batra said.
  • Outlook: Waters sees Q2 revenue of $695.3 million - $708.9 million versus the consensus of $706.5 million. Waters sees non-GAAP EPS of $2.55 - $2.65, below the consensus of $2.78. 
  • Waters raised constant currency sales growth outlook to 7.5% - 9% (prior view 5% - 7%), representing sales of $2.91 billion - $2.95 billion versus the consensus of $2.93 billion. Waters sees non-GAAP EPS of $11.90 - $12.10 (prior view $11.75 - $12.00) versus the consensus of $11.9. 
  • Price Action: WAT shares are trading 7.69% higher at $325.73 on the last check Tuesday.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceMoversTechTrading IdeasBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...